γ‐Hydroxybutyrate and the GABAergic footprint: a metabolomic approach to unpicking the actions of GHB

• Published in: Journal of neurochemistry 2010-10, Vol.115 (1), p.58-67
• Main Authors: Nasrallah, Fatima A., Maher, Anthony D., Hanrahan, Jane R., Balcar, Vladimir J., Rae, Caroline D.
• Format: Article
• Language: English
• Subjects: 13C metabolism; Animals; Biological and medical sciences; Central nervous system; Central neurotransmission. Neuromudulation. Pathways and receptors; Cerebral Cortex - drug effects; Cerebral Cortex - metabolism; Data Interpretation, Statistical; DNA Fingerprinting; Dose-Response Relationship, Drug; Fundamental and applied biological sciences. Psychology; GABA Plasma Membrane Transport Proteins - genetics; GABA Plasma Membrane Transport Proteins - metabolism; GABA(A)rho; gamma-Aminobutyric Acid - metabolism; gamma‐hydroxybutyrate; Guinea Pigs; In Vitro Techniques; Ligands; Magnetic Resonance Spectroscopy; Metabolomics; NMR spectroscopy; Pattern Recognition, Automated; Principal Component Analysis; Pyruvic Acid - metabolism; Receptors, Drug - drug effects; Receptors, GABA - genetics; Receptors, GABA - metabolism; Receptors, GABA-B - drug effects; Receptors, GABA-B - genetics; Receptors, GABA-B - metabolism; Sodium Oxybate - pharmacology; Somesthesis and somesthetic pathways (proprioception, exteroception, nociception); interoception; electrolocation. Sensory receptors; Vertebrates: nervous system and sense organs
• ISSN: 0022-3042; 1471-4159
• DOI: 10.1111/j.1471-4159.2010.06901.x

J. Neurochem. (2010) 115, 58–67. Gamma‐hydroxybutyrate is found both naturally in the brain and self‐administered as a drug of abuse. It has been reported to act at endogenous γ‐hydroxybutyrate (GHB) receptors and GABA(B) receptors [GABA(B)R], and may also be metabolized to GABA. Here, the metabolic fingerprints of a range of concentrations of GHB were measured in brain cortical tissue slices and compared with those of ligands active at GHB and GABA‐R using principal components analysis (PCA) to identify sites of GHB activity. Low concentrations of GHB (1.0 μM) produced fingerprints similar to those of ligands active at GHB receptors and α4‐containing GABA(A)R. A total of 10 μM GHB clustered proximate to mainstream GABAergic synapse ligands, such as 1.0 μM baclofen, a GABA(B)R agonist. Higher concentrations of GHB (30 μM) clustered with GABA(C)R agonists and the metabolic responses induced by blockade of the GABA transporter‐1 (GAT1). The metabolic responses induced by 60 and 100 μM GHB were mimicked by simultaneous blockade of GAT1 and GAT3, addition of low concentrations of GABA(C)R antagonists, or increasing cytoplasmic GABA concentrations by incubation with the GABA transaminase inhibitor vigabatrin. These data suggest that at concentrations > 30 μM, GHB may be active via metabolism to GABA, which is then acting upon an unidentified GABAergic master switch receptor (possibly a high‐affinity extrasynaptic receptor), or GHB may itself be acting directly on an extrasynaptic GABA‐R, capable of turning off large numbers of cells. These results offer an explanation for the steep dose–response curve of GHB seen in vivo, and suggest potential target receptors for further investigation.